Like all Paragon Biosciences companies, Harmony has understood the importance of establishing a great workplace culture right from their start, with patients at the heart of all they do. In 2017, we at Paragon founded …
The first FDA-cleared artificial intelligence diagnostic system for medical imaging, developed by Qlarity Imaging, a portfolio company of Paragon Biosciences, was selected as a “game-changing” innovation by a panel of global business leaders. Chicago, IL, …
– Acquisition complements and expands Castle Creek clinical development pipeline to include gene therapy platform – Strategic acquisition to result in advancement of multiple late-stage investigational therapies for epidermolysis bullosa and other rare conditions Exton, …
Read moreCastle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
The newly created financial services organization was formed to serve the rapid expansion of Paragon Biosciences’ portfolio of life science companies Chicago, IL, August 20, 2019 – Paragon Biosciences LLC – the Chicago-based life science …
Read moreParagon Biosciences Announces the Formation of Paragon Health Capital
Paragon Biosciences LLC, the Chicago-based life science innovator that invests in, builds, and advises bioscience companies, is announcing the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded to harness the value of artificial intelligence (AI) to improve medical outcomes.
Paragon Biosciences, LLC Chairman and CEO Jeff Aronin was recently recognized by the Northern Illinois University (NIU) College of Business as the 2019 recipient of their Innovation and Entrepreneurship Award.
The newly-created position is the result of rapid expansion at Paragon and its portfolio companies, which are developing novel medical treatments.
With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical conditions.
Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on.
Paragon Biosciences (Paragon) today announced the completion of a new capital investment of $71.8 million for Castle Creek Pharma (Castle Creek), a Paragon portfolio company.
Sign up with your email address to receive news and updates.
We respect your privacy.